HekeTiss has treated the first patient in its first-in-human Phase I/IIa clinical trial (RESCUE-PATCH), marking the initiation of clinical evaluation of TrophiPatch in chronic, non-healing wounds. The trial is sponsored by the Division of Dermatology at the University Hospitals of Geneva (HUG) and conducted in collaboration with HekeTiss.

This milestone represents a major step in the advancement of our regenerative approach and its translation into patient care.

The study includes patients with venous leg ulcers, diabetic foot ulcers, and mixed etiology wounds refractory to standard of care.

Further details are available on ClinicalTrials.gov (NCT07048054)